Skip to main content

Year: 2025

Shell plc Fourth Quarter 2024 Euro and GBP Equivalent Dividend Payments

SHELL PLC FOURTH QUARTER 2024 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS March 10, 2025 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the fourth quarter 2024 interim dividend, which was announced on January 30, 2025 at US$0.358 per ordinary share. Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by February 28, 2025 will be entitled to a dividend of US$0.358, €0.3315 or 27.79p per ordinary share, respectively. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent...

Continue reading

The sales of VILVI Group February 2025

VILVI Group, which consists of “Vilkyškių pieninė“ AB, “Modest” AB, “Kelmės pieninė“ AB, “Kelmės pienas” UAB, “Pieno logistika” AB and “Baltic Dairy Board” SIA, consolidated sales for February 2025 amounted EUR 22.12 million – 27.6% increase comparing to February 2024. The sales of the Group for period January – February 2025 amounted to 46.92 million EUR 31.1% increase comparing to the same period last year. Vilija Milaseviciute                                                                                     Economics and finance directorPhone: +370 441 55 102 Email: vilija.milaseviciute@vilvi.eu

Continue reading

Share repurchase programme: Transactions of week 10 2025

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 12,000 581.70 6,980,4253 March 2025 4,000 583.42 2,333,6724 March 2025 3,888 568.21 2,209,2075...

Continue reading

11/2025・Trifork Group: Weekly report on share buyback

Company announcement no. 11 / 2025Schindellegi, Switzerland – 10 March 2025 Trifork Group: Weekly report on share buyback On 28 Februay 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. The buyback program will not be active from 9 to 15 April 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share...

Continue reading

Methanex Provides Update on Geismar Operations

VANCOUVER, British Columbia, March 09, 2025 (GLOBE NEWSWIRE) — Methanex Corporation (TSX:MX) (Nasdaq:MEOH) announced today that its 1.8 million tonne methanol plant, Geismar 3 (G3), in Geismar, Louisiana was impacted by an unplanned outage in late February. Upon completing various inspections, management has decided to complete repairs to the autothermal reformer (ATR), and management currently estimates a plant startup by early May 2025. During this outage, management is taking the opportunity to bring forward the completion of other planned maintenance work on G3 which was part of a previously budgeted three-week outage which is no longer expected to be required. This outage is expected to primarily impact the second quarter financial results due to lower produced methanol sales. The cost of these repairs is not expected to be...

Continue reading

FTI Consulting Further Bolsters Asia Business Transformation Practice with Senior Appointments

SINGAPORE, March 09, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Zarif Munir as a Senior Managing Director and Head of Southeast Asia Business Transformation and Enqing Wang as a Managing Director in the firm’s Business Transformation practice within the Corporate Finance & Restructuring segment. Luke Schaeffer, Global Leader of Strategy and Transformation at FTI Consulting, said, “We are delighted to welcome Zarif and Enqing to our growing Business Transformation practice in Asia. Their expertise in business transformation, portfolio management and operational improvement will enable us to address critical challenges such as driving efficiency, unlocking growth opportunities and navigating complex market dynamics. Investing in these capabilities is essential as businesses in...

Continue reading

Financing Agreement Signed

A loan agreement has been signed between Reykjavík Energy and the Council of Europe Development Bank (CEB), as announced to the stock exchange on September 30, 2024, following the bank’s approval.The loan amount is EUR 75 million and will be used to develop heating and water utilities, including enhancing the resilience of utility systems against natural hazards. Contact:Snorri Hafsteinn Þorkelsson CFO snorri.hafsteinn.thorkelsson@orkuveitan.is

Continue reading

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the U.S. and the European Union TARRYTOWN, N.Y. and PARIS, March 08, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent® (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP). The data were shared...

Continue reading

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AADFive times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation...

Continue reading

Kaldalón hf.: Annual General Meeting 3 April 2025

The Board of Directors of Kaldalón hf. hereby announces that the Annual General Meeting of the company will be held on Wednesday, April 3, 2025, at 16:00 GMT. The meeting will be held at Reykjavík Natura, Nauthólsvegur 52, 101 Reykjavík. Enclosed is the agenda for the Annual General Meeting.  Meeting documents and further information concerning the meeting is available on the website kaldalon.is/adalfundur2025.  

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.